Jacob Funds, a mutual fund company, released its fourth-quarter 2025 investor letter. A copy of the same can be downloaded ...

Cabaletta (David Egan, whip up) beats Lady G (Hollie Doyle,right) in the bet365 Aphrodite Fillies’ Stakes Newbury 18.7.20 Edward Whitaker/Racing Post Cabaletta (David Egan, nearest) beats Lady G ...

Cabaletta Bio (NASDAQ:CABA) executives told investors at the Guggenheim Emerging Outlook Biotech Summit 2026 that the company has initiated enrollment in what it described as its first pivotal program ...

– Registrational cohort enrollment in RESET-Myositis™ trial on track to start in 2H25 with anticipated 2027 BLA submission for rese-cel in myositis – – Five disease-specific cohorts fully enrolled in ...

Cabaletta didn't have any major announcements or any Securities and Exchange Commission (SEC) filings to make the stock rise. However, Guggenheim initiated coverage of the stock, with a price target ...

The MarketWatch News Department was not involved in the creation of this content. -- All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational ...

Cabaletta Bio (CABA) has attracted fresh attention after presenting early data from its RESET-PV clinical trial at the ESGCT Congress. The company reported that its CAR T cell therapy, rese-cel, ...

(RTTNews) - Biotechnology company Cabaletta Bio, Inc. (CABA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CABA-201, a 4-1BB-containing fully ...

PHILADELPHIA--(BUSINESS WIRE)--Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B ...

Registrational myositis trial actively enrolling with planned 17-patient cohort and 2027 rese-cel BLA submission - including an outpatient dosing option using a single weight-based dose IND amendment ...

Cabaletta Bio focuses on autoimmune diseases with a potential best-in-class cell therapy, CABA-201, showing promise in early studies. Its stock price rose >$25 due to positive data produced by a drug ...

– Nine patients enrolled as of August 5, 2024 across the RESET™ clinical development program, including four since EULAR in June, with 22 U.S. clinical sites now enrolling – – Additional clinical data ...